

Docket No. 0471-0286PUS1

AMENDMENTS TO THE CLAIMS

1. **(Previously Presented)** Use of benzyl ester of hyaluronic acid or a cross-linked derivative of hyaluronic acid wherein the carboxy groups of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule, for the preparation of a biomaterial suitable for antiangiogenic therapy to treat primary and secondary tumours.
2. **(Previously Presented)** The use according to claim 1 wherein hyaluronic acid is in association with other natural, synthetic and/or semisynthetic biopolymers.
3. **(Previously Presented)** The use according to claim 2, wherein the natural biopolymer is selected from the group consisting of collagen, cellulose, polysaccharides, chitin, chitosan, pectins, agar, gellan and alginic acid.
4. **(Previously Presented)** The use according to claim 2, wherein the synthetic biopolymer is selected from the group consisting of polylactic acid (PLA), polyglycolic acid (PGA), polyurethanes and polysulphonic resins.
5. **(Previously Presented)** The use according to claim 2, wherein the semisynthetic biopolymer is selected from the group consisting of collagen cross-linked with aldehydes, diamine and gellan.
6. **(Previously Presented)** The use according to claim 1 wherein the biomaterial is associated with pharmacologically active substances.
7. **(Previously Presented)** The use according to claim 6, wherein the pharmacologically active substance is selected from the group consisting of fluorouracil, methotrexate, cis-platinum, carboplatin, oxaliplatin, ethopoxide, cyclophosphamide, vincristine, doxorubicin.
8. **(Previously Presented)** The use according to any one of claims 1-7 wherein the biomaterial is in the form of a non-woven felt, sponge, microsphere, film or membrane and/or other three-dimensional structures.
9. **(Currently Amended)** The use according to ~~any one of claims 1-8~~ claim 8, for the treatment and care of primary and secondary tumours when the tumour has been surgically removed and the cavity that is thus formed requires filling.

10. (New) A method for the treatment and care of primary and secondary tumors which comprises filling a cavity resulting from the surgical removal of a tumor with a benzyl ester of hyaluronic acid or a cross-linked derivative of hyaluronic acid wherein the carboxy groups of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule.

11. (New) The method according to claim 10 wherein hyaluronic acid is in association with other natural, synthetic and/or semisynthetic biopolymers.

12. (New) The method according to claim 2, wherein the natural biopolymer is selected from the group consisting of collagen, cellulose, polysaccharides, chitin, chitosan, pectins, agar, gellan and alginic acid.

13. (New) The method according to claim 2, wherein the synthetic biopolymer is selected from the group consisting of polylactic acid (PLA), polyglycolic acid (PGA), polyurethanes and polysulphonic resins.

14. (New) The method according to claim 2, wherein the semisynthetic biopolymer is selected from the group consisting of collagen cross-linked with aldehydes, diamine and gellan.

15. (New) The method according to claim 10 wherein the biomaterial is associated with at least one pharmacologically active substance.

16. (New) The method according to claim 15, wherein the pharmacologically active substance is selected from the group consisting of fluorouracil, methotrexate, cis-platinum, carboplatin, oxaliplatin, ethopoxide, cyclophosphamide, vincristine, and doxorubicin.

17. (New) The method according to any one of claims 10-16 wherein the biomaterial is in the form of a non-woven felt, sponge, microsphere, film or membrane and/or other three-dimensional structure.